Prognostic value of systemic immune‐inflammation index in CAD patients: Systematic review and meta‐analyses

Author:

Zhao Zehao1ORCID,Zhang Xiaoming1,Sun Tienan1,Huang Xin1,Ma Meishi2,Yang Shiwei123,Zhou Yujie123

Affiliation:

1. Department of Cardiology, Beijing Anzhen Hospital Capital Medical University Beijing China

2. Beijing Institute of Heart, Lung and Blood Vessel Disease Beijing China

3. Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease Capital Medical University Beijing China

Abstract

AbstractBackgroundSystemic immune‐inflammation index (SII) is a novel inflammatory marker based on neutrophils, platelets and lymphocytes counts, which has potential prognostic value among coronary artery disease (CAD) patients as described by some observational studies. We aimed to provide higher‐certainty evidence to verify the association of SII with poor outcomes of CAD patients.MethodsPubMed, Web of Science, Embase, Ovid and Scopus were searched to find relevant literature exploring the prognostic value of SII among CAD patients. Hazard ratios (HRs) with 95% confidence intervals (CIs) extracted from the literature included were pooled with the fixed‐effect or random‐effect model. Sensitivity analyses and subgroup analyses were conducted to detect the source of heterogeneity and evaluate the stability of results.ResultsA total of nine studies with 15,832 participants were included. The quantitative synthesis including eight studies with 15,657 participants showed that the high SII was related to the major adverse cardiovascular event in CAD patients (HR with 95% CI: 2.36 [1.67, 3.33]). After eliminating heterogeneity and adjusting for publication bias, the above result was still robust (HR with 95% CI: 1.67 [1.32, 2.12]). Additionally, we also demonstrated the prognostic values of SII for all‐cause death, cardiovascular death, myocardial infarction and stroke.ConclusionHigher SII has prognostic values for adverse outcomes in CAD patients.

Funder

National Key Research and Development Program of China

Publisher

Wiley

Subject

Clinical Biochemistry,Biochemistry,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3